These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21761363)

  • 21. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR; Gilbert RE; Yue DK
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.
    Massi Benedetti M; Humburg E; Dressler A; Ziemen M
    Horm Metab Res; 2003 Mar; 35(3):189-96. PubMed ID: 12734781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy.
    Dündar BN; Dündar N; Eren E
    J Clin Res Pediatr Endocrinol; 2009; 1(4):181-7. PubMed ID: 21274293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin.
    Fiesselmann A; Wiesner T; Fleischmann H; Bramlage P
    Acta Diabetol; 2016 Oct; 53(5):717-26. PubMed ID: 27093968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
    Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain.
    Delgado E;
    Int J Clin Pract; 2012 Mar; 66(3):281-8. PubMed ID: 22340448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoglycemia with insulin in post-transplant diabetes mellitus.
    Chandra A; Rao N; Pooniya V; Singh A
    Transpl Immunol; 2023 Jun; 78():101833. PubMed ID: 37024062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved glycemic control with decreased hypoglycemia prevents long-term complications in type 2 diabetes patients: long-term simulation analysis using the "diabetes mellitus model".
    Maxion-Bergemann S; Huppertz E; Jacobs LD; Müller E; Walleser S
    Int J Clin Pharmacol Ther; 2005 Jun; 43(6):271-81. PubMed ID: 15968884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
    Yki-Järvinen H; Dressler A; Ziemen M;
    Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.
    Rosenstock J; Schwartz SL; Clark CM; Park GD; Donley DW; Edwards MB
    Diabetes Care; 2001 Apr; 24(4):631-6. PubMed ID: 11315821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly.
    Varewijck AJ; Janssen JA; Vähätalo M; Hofland LJ; Lamberts SW; Yki-Järvinen H
    Diabetologia; 2012 Apr; 55(4):1186-94. PubMed ID: 22237688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: the COBIN2 study.
    Zdarska DJ; Kvapil M; Rusavy Z; Krcma M; Broz J; Krivska B; Kadlecova P
    Wien Klin Wochenschr; 2014 Apr; 126(7-8):228-37. PubMed ID: 24563017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
    Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus.
    Liu M; Zhou Z; Yan J; Li P; Song W; Fu J; Chen X; Zhao W; Xi L; Luo X; Sha L; Deng X; Gong C
    BMC Endocr Disord; 2016 Nov; 16(1):67. PubMed ID: 27887605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin.
    Siegmund T; Weber S; Blankenfeld H; Oeffner A; Schumm-Draeger PM
    Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):349-53. PubMed ID: 17701878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
    Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
    Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database.
    Laubner K; Molz K; Kerner W; Karges W; Lang W; Dapp A; Schütt M; Best F; Seufert J; Holl RW
    Diabetes Metab Res Rev; 2014 Jul; 30(5):395-404. PubMed ID: 24302583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients.
    Pan CY; Sinnassamy P; Chung KD; Kim KW;
    Diabetes Res Clin Pract; 2007 Apr; 76(1):111-8. PubMed ID: 17011662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.